Main patient characteristics
| Characteristic . | OM-CMML (n = 42) . | D-CMML (n = 120) . | P-CMML (n = 42) . | P (OM-CMML vs D-CMML) . | P (OM-CMML vs P-CMML) . | P (D-CMML vs P-CMML) . |
|---|---|---|---|---|---|---|
| Median age (range) (IQR), y | 77 (44-90) (69-83) | 77 (39-94) (70-82) | 77 (63-89) (71-83) | .789 | .488 | .596 |
| Sex, n (%) | ||||||
| Male | 28 (66.7) | 68 (56.7) | 28 (66.7) | .256 | .99 | .256 |
| Female | 14 (33.3) | 52 (43.3) | 14 (33.3) | |||
| Median hemoglobin (range) (IQR), g/L | 114.5 (73-150) (105-127.5) | 121 (74-161) (106.3-135.8) | 115 (69-161) (98-128) | .150 | .949 | .160 |
| Median WBC count (range) (IQR), ×109/L | 4.51 (2.49-7.18) (3.64-5.35) | 7.33 (2.94-12.70) (5.25-9.08) | 20.80 (13.12-53.1) (16.82-28.26) | <.001 | <.001 | <.001 |
| Median neutrophil count (range) (IQR), ×109/L | 1.91 (0.38-4.42) (1.15-2.67) | 3.15 (0.50-13.4) (2.02-4.65) | 12.69 (2.81-36.80) (9.66-19.28) | <.001 | <.001 | <.001 |
| Median platelet count (range) (IQR), ×109/L | 135 (29-318) (89.8-177.3) | 116.5 (12-640) (82.3-174.5) | 146 (15-500) (92.5-227) | .627 | .379 | .190 |
| Median monocyte, (range) (IQR), ×109/L | 0.71 (0.53-0.96) (0.66-0.84) | 1.64 (1.00-4.50) (1.23-2.01) | 4.22 (1.30-13.96) (2.75-6.93) | <.001 | <.001 | <.001 |
| Median PB monocyte %, (range) (IQR) | 17 (10-26.2) (14-20) | 24.1 (10.8-54.4) (19.4-27.9) | 20.4 (10-61.8) (15.2-26-2) | <.001 | .034 | .018 |
| Median BM monocyte %, (range) (IQR) | 5 (1-13) (3-7) | 8 (0-19) (6-11) | 9 (1-19) (5-12) | <.001 | .004 | .625 |
| Presence PB blasts, n (%) | 2 (4.8) | 7 (5.8) | 12 (30) | .99 | .003 | <.001 |
| Median BM blast count %, (range) (IQR) | 4 (0-12) (3-6) | 8 (1-19) (5-12) | 7 (0-8) (3-12) | <.001 | .026 | .294 |
| Median dyserythropoiesis, (range) (IQR), % | 29 (0-80) (19-52) | 24 (0-90) (11-37) | 18 (0-90) (6-27) | .071 | .008 | .162 |
| Median dysgranulopoiesis (range) (IQR), % | 45 (0-100) (30-70) | 50 (0-98) (26-71) | 45 (0-83) (25-65) | .543 | .984 | .542 |
| Median dysthrombopoiesis (range) (IQR), % | 12 (0-64) (0-21) | 8 (0-69) (0-17) | 13 (0-90) (2-29) | .474 | .504 | .182 |
| Karyotype, abnormal/total cases (%) | 12 (29.3) | 24 (21.4) | 7 (18.9) | .311 | .288 | .744 |
| Spanish cytogenetic group, n (%) | ||||||
| Low | 35 (85.4) | 101 (89.4) | 33 (89.2) | .606 | .881 | .835 |
| Intermediate | 3 (7.3) | 4 (3.5) | 2 (5.4) | |||
| High | 3 (7.3) | 8 (7.1) | 2 (5.4) | |||
| Mayo prognostic model, n (%) | ||||||
| Low | 22 (53.7) | 51 (42.9) | 6 (15) | .357 | <.001 | .003 |
| Intermediate | 15 (36.6) | 47 (39.5) | 20 (50) | |||
| High | 4 (9.8) | 21 (17.6) | 14 (35) | |||
| CPSS, n (%) | ||||||
| Low (low and intermediate-1) | 35 (85.4) | 101 (87.8) | 21 (58.3) | .686 | .008 | <.001 |
| High (intermediate-2 and high) | 6 (14.6) | 14 (12.2) | 15 (41.7) | |||
| CPSS-P, n (%) | ||||||
| Low (low and intermediate-1) | 33 (80.5) | 86 (74.8) | 17 (47.2) | .461 | .002 | .002 |
| High (intermediate-2 and high) | 8 (19.5) | 29 (25.2) | 19 (52.8) | |||
| CPSS-mol, n (%) | ||||||
| Low (low and intermediate-1) | 26 (66.7) | 27 (58.7) | 3 (27.3) | .450 | .036 | .093 |
| High (intermediate-2 and high) | 13 (33.3) | 19 (41.3) | 8 (72.7) | |||
| 2017 WHO classification, n (%) | ||||||
| CMML-0 | 23 (54.8) | 24 (20) | 10 (23.8) | <.001 | .004 | .755 |
| CMML-1 | 14 (33.3) | 54 (45) | 16 (38.1) | |||
| CMML-2 | 5 (11.9) | 42 (35) | 16 (38.1) | |||
| Median MO1% (range) (IQR) | 96.1 (82.3-99.6) (94.0-97.5) | 97.7 (80.5-99.5) (95.9-98.7) | 99 (87.6-100) (96.1-99.6) | .004 | .002 | .052 |
| MO1 >94%, n (%) | 31 (77.5) | 34 (89.5) | 15 (93.8) | .226 | .251 | .99 |
| Patients with mutations, n (%) | 41/41 (100) | 36/37 (97.3) | 16/16 (100) | .474 | .99 | .99 |
| Mutated genes, median (range) (IQR) | 2 (1-8) (2-3) | 2 (0-5) (1-3) | 4 (2-5) (3-4) | .463 | <.001 | <.001 |
| Number of mutations, median (range) (IQR) | 3 (1-9) (2-4) | 3 (0-9) (2-4) | 5 (2-7) (4-6) | .819 | <.001 | .004 |
| ASXL1 mutation, n (%) | 7/41 (17.1) | 5/37 (13.5) | 10/16 (62.5) | .66 | .001 | <.001 |
| CALR mutation, n (%) | — | — | — | — | — | — |
| CBL mutation, n (%) | 1/41 (2.4) | 6/37 (16.2) | 5/16 (31.3) | .048 | .005 | .215 |
| CSF3R mutation, n (%) | — | — | — | — | — | — |
| DNMT3A mutation, n (%) | 6/41 (14.6) | 3/37 (8.1) | — | .49 | .17 | .55 |
| ETV6 mutation, n (%) | 1/41 (2.4) | 1/37 (2.7) | — | .99 | .99 | .99 |
| EZH2 mutation, n (%) | 2/41 (4.9) | — | 1/16 (6.3) | .50 | .99 | .30 |
| IDH1 mutation, n (%) | 2/41 (4.9) | — | — | .50 | .99 | — |
| IDH2 mutation, n (%) | 3/41 (7.3) | 1/37 (2.7) | 3/16 (18.8) | .62 | .34 | .08 |
| JAK2 mutation, n (%) | 2/41 (4.9) | 4/37 (10.8) | 1/16 (6.3) | .42 | .99 | .99 |
| KIT mutation, n (%) | — | — | — | — | — | — |
| KRAS mutation, n (%) | 1/41 (2.4) | 4/37 (10.8) | 2/16 (12.5) | .18 | .19 | .99 |
| MPL mutation, n (%) | — | — | 1/16 (6.3) | — | .28 | .30 |
| NRAS mutation, n (%) | 1/41 (2.4) | 3/37 (8.1) | 3/16 (18.8) | .34 | .06 | .35 |
| PRPF8 mutation, n (%) | — | 1/37 (2.7) | — | .47 | — | .99 |
| RUNX1 mutation, n (%) | 5/41 (12.2) | 4/37 (10.8) | 3/16 (18.8) | .99 | .67 | .99 |
| SETBP1 mutation, n (%) | 2/41 (4.9) | 1/37 (2.7) | 1/16 (6.3) | .99 | .99 | .52 |
| SF3B1 mutation, n (%) | 11/41 (26.8) | 6/37 (16.2) | 3/16 (18.8) | .26 | .34 | .99 |
| SH2B3 mutation, n (%) | 2/41 (4.9) | 1/37 (2.7) | 2/16 (12.5) | .99 | .31 | .21 |
| SRSF2 mutation, n (%) | 12/41 (29.3) | 7/37 (18.9) | 7/16 (43.8) | .29 | .30 | .06 |
| STAG2 mutation, n (%) | 2/41 (4.9) | — | — | .50 | .99 | — |
| TET2 mutation, n (%) | 30/41 (73.2) | 27/37 (73) | 13/16 (81.3) | .98 | .74 | .73 |
| TP53 mutation, n (%) | 1/41 (2.4) | 3/37 (8.1) | 1/16 (6.3) | .34 | .50 | .99 |
| U2AF1 mutation, n (%) | 1/41 (2.4) | 1/37 (2.7) | 2/16 (12.5) | .99 | .19 | .21 |
| ZRSR2 mutation, n (%) | 8/41 (19.5) | 4/37 (10.8) | — | .36 | .09 | .30 |
| RAS-pathway, n (%) | 2/41 (4.9) | 10/37 (27) | 10/16 (62.5) | .010 | <.001 | .014 |
| Characteristic . | OM-CMML (n = 42) . | D-CMML (n = 120) . | P-CMML (n = 42) . | P (OM-CMML vs D-CMML) . | P (OM-CMML vs P-CMML) . | P (D-CMML vs P-CMML) . |
|---|---|---|---|---|---|---|
| Median age (range) (IQR), y | 77 (44-90) (69-83) | 77 (39-94) (70-82) | 77 (63-89) (71-83) | .789 | .488 | .596 |
| Sex, n (%) | ||||||
| Male | 28 (66.7) | 68 (56.7) | 28 (66.7) | .256 | .99 | .256 |
| Female | 14 (33.3) | 52 (43.3) | 14 (33.3) | |||
| Median hemoglobin (range) (IQR), g/L | 114.5 (73-150) (105-127.5) | 121 (74-161) (106.3-135.8) | 115 (69-161) (98-128) | .150 | .949 | .160 |
| Median WBC count (range) (IQR), ×109/L | 4.51 (2.49-7.18) (3.64-5.35) | 7.33 (2.94-12.70) (5.25-9.08) | 20.80 (13.12-53.1) (16.82-28.26) | <.001 | <.001 | <.001 |
| Median neutrophil count (range) (IQR), ×109/L | 1.91 (0.38-4.42) (1.15-2.67) | 3.15 (0.50-13.4) (2.02-4.65) | 12.69 (2.81-36.80) (9.66-19.28) | <.001 | <.001 | <.001 |
| Median platelet count (range) (IQR), ×109/L | 135 (29-318) (89.8-177.3) | 116.5 (12-640) (82.3-174.5) | 146 (15-500) (92.5-227) | .627 | .379 | .190 |
| Median monocyte, (range) (IQR), ×109/L | 0.71 (0.53-0.96) (0.66-0.84) | 1.64 (1.00-4.50) (1.23-2.01) | 4.22 (1.30-13.96) (2.75-6.93) | <.001 | <.001 | <.001 |
| Median PB monocyte %, (range) (IQR) | 17 (10-26.2) (14-20) | 24.1 (10.8-54.4) (19.4-27.9) | 20.4 (10-61.8) (15.2-26-2) | <.001 | .034 | .018 |
| Median BM monocyte %, (range) (IQR) | 5 (1-13) (3-7) | 8 (0-19) (6-11) | 9 (1-19) (5-12) | <.001 | .004 | .625 |
| Presence PB blasts, n (%) | 2 (4.8) | 7 (5.8) | 12 (30) | .99 | .003 | <.001 |
| Median BM blast count %, (range) (IQR) | 4 (0-12) (3-6) | 8 (1-19) (5-12) | 7 (0-8) (3-12) | <.001 | .026 | .294 |
| Median dyserythropoiesis, (range) (IQR), % | 29 (0-80) (19-52) | 24 (0-90) (11-37) | 18 (0-90) (6-27) | .071 | .008 | .162 |
| Median dysgranulopoiesis (range) (IQR), % | 45 (0-100) (30-70) | 50 (0-98) (26-71) | 45 (0-83) (25-65) | .543 | .984 | .542 |
| Median dysthrombopoiesis (range) (IQR), % | 12 (0-64) (0-21) | 8 (0-69) (0-17) | 13 (0-90) (2-29) | .474 | .504 | .182 |
| Karyotype, abnormal/total cases (%) | 12 (29.3) | 24 (21.4) | 7 (18.9) | .311 | .288 | .744 |
| Spanish cytogenetic group, n (%) | ||||||
| Low | 35 (85.4) | 101 (89.4) | 33 (89.2) | .606 | .881 | .835 |
| Intermediate | 3 (7.3) | 4 (3.5) | 2 (5.4) | |||
| High | 3 (7.3) | 8 (7.1) | 2 (5.4) | |||
| Mayo prognostic model, n (%) | ||||||
| Low | 22 (53.7) | 51 (42.9) | 6 (15) | .357 | <.001 | .003 |
| Intermediate | 15 (36.6) | 47 (39.5) | 20 (50) | |||
| High | 4 (9.8) | 21 (17.6) | 14 (35) | |||
| CPSS, n (%) | ||||||
| Low (low and intermediate-1) | 35 (85.4) | 101 (87.8) | 21 (58.3) | .686 | .008 | <.001 |
| High (intermediate-2 and high) | 6 (14.6) | 14 (12.2) | 15 (41.7) | |||
| CPSS-P, n (%) | ||||||
| Low (low and intermediate-1) | 33 (80.5) | 86 (74.8) | 17 (47.2) | .461 | .002 | .002 |
| High (intermediate-2 and high) | 8 (19.5) | 29 (25.2) | 19 (52.8) | |||
| CPSS-mol, n (%) | ||||||
| Low (low and intermediate-1) | 26 (66.7) | 27 (58.7) | 3 (27.3) | .450 | .036 | .093 |
| High (intermediate-2 and high) | 13 (33.3) | 19 (41.3) | 8 (72.7) | |||
| 2017 WHO classification, n (%) | ||||||
| CMML-0 | 23 (54.8) | 24 (20) | 10 (23.8) | <.001 | .004 | .755 |
| CMML-1 | 14 (33.3) | 54 (45) | 16 (38.1) | |||
| CMML-2 | 5 (11.9) | 42 (35) | 16 (38.1) | |||
| Median MO1% (range) (IQR) | 96.1 (82.3-99.6) (94.0-97.5) | 97.7 (80.5-99.5) (95.9-98.7) | 99 (87.6-100) (96.1-99.6) | .004 | .002 | .052 |
| MO1 >94%, n (%) | 31 (77.5) | 34 (89.5) | 15 (93.8) | .226 | .251 | .99 |
| Patients with mutations, n (%) | 41/41 (100) | 36/37 (97.3) | 16/16 (100) | .474 | .99 | .99 |
| Mutated genes, median (range) (IQR) | 2 (1-8) (2-3) | 2 (0-5) (1-3) | 4 (2-5) (3-4) | .463 | <.001 | <.001 |
| Number of mutations, median (range) (IQR) | 3 (1-9) (2-4) | 3 (0-9) (2-4) | 5 (2-7) (4-6) | .819 | <.001 | .004 |
| ASXL1 mutation, n (%) | 7/41 (17.1) | 5/37 (13.5) | 10/16 (62.5) | .66 | .001 | <.001 |
| CALR mutation, n (%) | — | — | — | — | — | — |
| CBL mutation, n (%) | 1/41 (2.4) | 6/37 (16.2) | 5/16 (31.3) | .048 | .005 | .215 |
| CSF3R mutation, n (%) | — | — | — | — | — | — |
| DNMT3A mutation, n (%) | 6/41 (14.6) | 3/37 (8.1) | — | .49 | .17 | .55 |
| ETV6 mutation, n (%) | 1/41 (2.4) | 1/37 (2.7) | — | .99 | .99 | .99 |
| EZH2 mutation, n (%) | 2/41 (4.9) | — | 1/16 (6.3) | .50 | .99 | .30 |
| IDH1 mutation, n (%) | 2/41 (4.9) | — | — | .50 | .99 | — |
| IDH2 mutation, n (%) | 3/41 (7.3) | 1/37 (2.7) | 3/16 (18.8) | .62 | .34 | .08 |
| JAK2 mutation, n (%) | 2/41 (4.9) | 4/37 (10.8) | 1/16 (6.3) | .42 | .99 | .99 |
| KIT mutation, n (%) | — | — | — | — | — | — |
| KRAS mutation, n (%) | 1/41 (2.4) | 4/37 (10.8) | 2/16 (12.5) | .18 | .19 | .99 |
| MPL mutation, n (%) | — | — | 1/16 (6.3) | — | .28 | .30 |
| NRAS mutation, n (%) | 1/41 (2.4) | 3/37 (8.1) | 3/16 (18.8) | .34 | .06 | .35 |
| PRPF8 mutation, n (%) | — | 1/37 (2.7) | — | .47 | — | .99 |
| RUNX1 mutation, n (%) | 5/41 (12.2) | 4/37 (10.8) | 3/16 (18.8) | .99 | .67 | .99 |
| SETBP1 mutation, n (%) | 2/41 (4.9) | 1/37 (2.7) | 1/16 (6.3) | .99 | .99 | .52 |
| SF3B1 mutation, n (%) | 11/41 (26.8) | 6/37 (16.2) | 3/16 (18.8) | .26 | .34 | .99 |
| SH2B3 mutation, n (%) | 2/41 (4.9) | 1/37 (2.7) | 2/16 (12.5) | .99 | .31 | .21 |
| SRSF2 mutation, n (%) | 12/41 (29.3) | 7/37 (18.9) | 7/16 (43.8) | .29 | .30 | .06 |
| STAG2 mutation, n (%) | 2/41 (4.9) | — | — | .50 | .99 | — |
| TET2 mutation, n (%) | 30/41 (73.2) | 27/37 (73) | 13/16 (81.3) | .98 | .74 | .73 |
| TP53 mutation, n (%) | 1/41 (2.4) | 3/37 (8.1) | 1/16 (6.3) | .34 | .50 | .99 |
| U2AF1 mutation, n (%) | 1/41 (2.4) | 1/37 (2.7) | 2/16 (12.5) | .99 | .19 | .21 |
| ZRSR2 mutation, n (%) | 8/41 (19.5) | 4/37 (10.8) | — | .36 | .09 | .30 |
| RAS-pathway, n (%) | 2/41 (4.9) | 10/37 (27) | 10/16 (62.5) | .010 | <.001 | .014 |
MO1%, percentage of classical monocytes (CD14++CD16-); RAS-pathway, mutations in CBL, NRAS, and/or KRAS gene; WBC, white blood cell.